Answering the CDMO shortage: A new paradigm for drug development

Photo by Isaac Quesada on Unsplash

What can the pharma industry do about the critical shortage of contract manufacturing organization (CMO) and contract development and manufacturing company (CDMO) facilities?

For a growing number of young entrepreneurial drug companies, the answer is a middle ground between building their own facilities and outsourcing to the saturated CMO/CDMO market. This middle ground lies in hybrid flexible cleanroom facilities with wraparound support services, which are gaining greater acceptance in the pharma industry. This model allows companies to leverage their manufacturing expertise while still maintaining control of their intellectual property. This approach is particularly valuable as new therapeutic technologies emerge, which require a different competency than many of the existing CMO/CDMO facilities can handle. Hybrid flexible cleanroom facilities are likely to emerge as a n…

Read more
  • 0